Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration

被引：724

作者：

Rosenfeld, PJ ^{[1
]}

Moshfeghi, AA ^{[1
]}

Puliafito, CA ^{[1
]}

机构：

[1] Univ Miami, Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA

来源：

OPHTHALMIC SURGERY LASERS & IMAGING | 2005年 / 36卷 / 04期

关键词：

D O I：

10.3928/1542-8877-20050701-14

中图分类号：

R77 [眼科学];

学科分类号：

100212 [眼科学];

摘要：

To determine whether intravitreal bevacizumab could improve optical coherence tomography and visual acuity outcomes in a patient with neovascular age-related macular degeneration who was responding poorly to pegaptanib therapy, an intravitreal injection of bevacizumab (1.0 mg) was given. Within 1 week, optical coherence tomography revealed resolution of the subretinal fluid, resulting in a normal-appearing macular contour. The improved macular appearance was maintained for at least 4 weeks, and visual acuity remained stable. No inflammation was observed. An intravitreal injection of bevacizumab may provide an effective, safe, and inexpensive option for patients with age-related macular degeneration who are losing vision secondary to macular neovascularization.

引用

页码：331 / 335

页数：5

共 10 条

[1]

The role of vascular endothelial growth factor \in ocular health and disease [J].

Adamis, AP ;

Shima, DT .

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2005, 25 (02) :111-118

[2]

BerminghamMcDonogh O, 1996, DEVELOPMENT, V122, P1427

[3]

Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen [J].

Chen, Y ;

Wiesmann, C ;

Fuh, G ;

Li, B ;

Christinger, HW ;

McKay, P ;

de Vos, AM ;

Lowman, HB .

JOURNAL OF MOLECULAR BIOLOGY, 1999, 293 (04) :865-881

[4]

Vascular endothelial growth factor: Basic science and clinical progress [J].

Ferrara, N .

ENDOCRINE REVIEWS, 2004, 25 (04) :581-611

[5]

Pegaptanib for neovascular age-related macular degeneration [J].

Gragoudas, ES ;

Adamis, AP ;

Cunningham, ET ;

Feinsod, M ;

Guyer, DR .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27) :2805-2816

[6]

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].

Hurwitz, H ;

Fehrenbacher, L ;

Novotny, W ;

Cartwright, T ;

Hainsworth, J ;

Heim, W ;

Berlin, J ;

Baron, A ;

Griffing, S ;

Holmgren, E ;

Ferrara, N ;

Fyfe, G ;

Rogers, B ;

Ross, R ;

Kabbinavar, F .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342

[7]

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration - Twelve-week results of an uncontrolled open-label clinical study [J].

Michels, S ;

Rosenfeld, PJ ;

Puliafito, CA ;

Marcus, EN ;

Venkatraman, AS .

OPHTHALMOLOGY, 2005, 112 (06) :1035-1047

[8]

MICHELS S, 2004, RETIN PHYS, V1, P16

[9]

Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following lntravitreal administration [J].

Mordenti, J ;

Cuthbertson, RA ;

Ferrara, N ;

Thomsen, K ;

Berleau, L ;

Licko, V ;

Allen, PC ;

Valverde, CR ;

Meng, YG ;

Fei, DTW ;

Fourre, KM ;

Ryan, AM .

TOXICOLOGIC PATHOLOGY, 1999, 27 (05) :536-544

[10]

Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation [J].

Mordenti, J ;

Thomsen, K ;

Licko, V ;

Berleau, L ;

Kahn, JW ;

Cuthbertson, RA ;

Duenas, ET ;

Ryan, AM ;

Schofield, C ;

Berger, TW ;

Meng, YG ;

Cleland, J .

TOXICOLOGICAL SCIENCES, 1999, 52 (01) :101-106

← 1 →